Hims & Hers Health, Inc. Class A Common Stock (HIMS)
51.96
+0.56 (1.09%)
NYSE · Last Trade: May 10th, 1:27 PM EDT
Detailed Quote
Previous Close
51.40
Open
49.43
Bid
51.75
Ask
51.94
Day's Range
48.87 - 52.22
52 Week Range
12.07 - 72.98
Volume
62,276,847
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
45,288,207
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $450 million aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on May 13, 2025, subject to customary closing conditions. Hims & Hers also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $130,000,000 aggregate principal amount of notes.
Hedge funds shorting Hims & Hers Health Inc (NYSE:HIMS) may regret it - earnings with a positive surprise could lead to a short squeeze as stock continues to rise, up 96% in past month.
Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Hims & Hers also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $67.5 million aggregate principal amount of notes.
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company’s new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale.
Hims & Hers Health shares have surged 32.4% since Tuesday's session open. The stock is gaining following a standout first-quarter earnings report released late Monday.
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 20.2% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat analysts' expectations on revenue, EPS, and EBITDA. Revenue more than doubled from last year driven by higher monthly spending per subscriber and a broader product mix tailored to personalized health needs. While subscriber growth slowed to 38% year over year, average revenue per user climbed over 50%, indicating deeper wallet share from existing customers and more engagement with premium offerings.
On the other hand, revenue guidance was softer than anticipated. Still, we think this was a decent quarter.
Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q1 CY2025, with sales up 111% year on year to $586 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $540 million was less impressive, coming in 2.4% below expectations. Its non-GAAP profit of $0.30 per share was 32.2% above analysts’ consensus estimates.
